UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors

PloS one, 2022-01, Vol.17 (3), p.e0264138

2022

Volltextzugriff (PDF)

Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer

The Journal of clinical investigation, 2016-06, Vol.126 (6), p.2334-2340

2016

Volltextzugriff (PDF)

Molecular determinants of response to PD-L1 blockade across tumor types

Nature communications, 2021-06, Vol.12 (1), p.3969-3969, Article 3969

2021

Volltextzugriff (PDF)

Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response

Cancer discovery, 2021-02, Vol.11 (2), p.282-292

2021

Volltextzugriff (PDF)

Understanding variants of unknown significance and classification of genomic alterations

The oncologist (Dayton, Ohio), 2024-08, Vol.29 (8), p.658-666

2024

Volltextzugriff (PDF)

Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting

Nature communications, 2021-03, Vol.12 (1), p.1382-15, Article 1382

2021

Volltextzugriff (PDF)

NF2 Tumor Suppressor Gene Inactivation in Advanced Papillary Renal Cell Carcinoma

The American journal of surgical pathology, 2021-05, Vol.45 (5), p.716-718

2021

Volltextzugriff (PDF)

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial

JAMA oncology, 2020-09, Vol.6 (9), p.1410

2020

Volltextzugriff (PDF)

PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-α inhibition

Proceedings of the National Academy of Sciences - PNAS, 2020-09, Vol.117 (39), p.24427-24433

2020

Volltextzugriff (PDF)

Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles

Modern pathology, 2020-08, Vol.33 (8), p.1466-1474

2020

Volltextzugriff (PDF)

Identification of NTRK fusions in pediatric mesenchymal tumors

Pediatric blood & cancer, 2017-08, Vol.64 (8), p.n/a

2017

Volltextzugriff (PDF)

Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib

JNCI : Journal of the National Cancer Institute, 2016-01, Vol.108 (1)

2016

Volltextzugriff (PDF)

Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations

Modern pathology, 2020-12, Vol.33 (12), p.2397-2406

2020

Volltextzugriff (PDF)

Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers

The oncologist (Dayton, Ohio), 2024-06, Vol.29 (6), p.493-503

2024

Volltextzugriff (PDF)

Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus

Clinical cancer research, 2018-04, Vol.24 (8), p.1881-1890

2018

Volltextzugriff (PDF)

Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board

The oncologist (Dayton, Ohio), 2023-01, Vol.28 (1), p.33-39

2023

Volltextzugriff (PDF)

Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer

Nature communications, 2022-12, Vol.13 (1), p.7495-7495, Article 7495

2022

Volltextzugriff (PDF)

Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient with Lung Adenocarcinoma following Treatment with Erlotinib and Osimertinib

Journal of thoracic oncology, 2019-02, Vol.14 (2), p.e27-e29

2019

Volltextzugriff (PDF)

Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1–KMT2A–YAP1 and VIM–KMT2A fusions

Modern pathology, 2020-11, Vol.33 (11), p.2307-2317

2020

Volltextzugriff (PDF)

Circulating Cell-Free DNA Yield and Circulating-Tumor DNA Quantity from Liquid Biopsies of 12 139 Cancer Patients

Clinical chemistry (Baltimore, Md.), 2021-11, Vol.67 (11), p.1554-1566

2021

Volltextzugriff (PDF)

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma

Nature communications, 2023-05, Vol.14 (1), p.2601-2601, Article 2601

2023

Volltextzugriff (PDF)

Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?

Lung cancer (Amsterdam, Netherlands), 2017-04, Vol.106, p.110-114

2017

Volltextzugriff (PDF)

Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features

Acta neuropathologica, 2020-07, Vol.140 (1), p.89-93

2020

Volltextzugriff (PDF)

1 – 25 von 171

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(163)
Mit Volltextzugriff
(134)

Publikationsform

Artikel
(167)
Berichte
(4)

Sprache

Englisch
(171)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors

Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer

Molecular determinants of response to PD-L1 blockade across tumor types

Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response

Understanding variants of unknown significance and classification of genomic alterations

Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting

NF2 Tumor Suppressor Gene Inactivation in Advanced Papillary Renal Cell Carcinoma

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial

PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-α inhibition

Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles

Identification of NTRK fusions in pediatric mesenchymal tumors

Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib

First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer

Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations

Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers

Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus

Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board

Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer

Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient with Lung Adenocarcinoma following Treatment with Erlotinib and Osimertinib

Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1–KMT2A–YAP1 and VIM–KMT2A fusions

Circulating Cell-Free DNA Yield and Circulating-Tumor DNA Quantity from Liquid Biopsies of 12 139 Cancer Patients

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma

Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?

BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer

Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features

Suchergebnisse filtern